Given the opposing roles of AMPK and mTOR, significant attention has been given to small molecules and other compounds capable of activating AMPK or inhibiting mTOR as a potential therapeutic strategy for the host-directed therapy against TB (Floto et al., 2007; Schiebler et al., 2015; Singh and Subbian, 2018). This evidence concerns the gene PRKAB1 and tuberculosis.